Risk Factors for Oral Mucositis During Chemotherapy Treatment for Solid Tumors: A Retrospective STROBE-Guided Study

Abstract Purpose This study retrospectively analyzed the risk factors for transchemotherapy oral mucositis (OM). Methods Before each chemotherapy cycle, patients were routinely evaluated for the presence/severity of OM based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effects and graded as follows: However, specific conditions such as mucositis are graded on a five-point scale: 0, absence of mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of pain and moderate ulceration, without interference with food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgent intervention). Information from 2 years of evaluations was collected and patient medical records were reviewed to obtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapy protocol, and history of head and neck radiotherapy. The X² test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p < 0.05). Results Among 19,000 total evaluations of 3,529 patients during 5.32 ± 4.7 chemotherapy cycles (CT) the prevalence of OM was 6.3% (n = 1,195). Chemotherapy duration (p < 0.001), female sex (p = 0.001), adjuvant intention (p = 0.008) and the use of carboplatin (p = 0.001), cisplatin (p = 0.029), docetaxel (p < 0.001) and bevacizumab (p = 0.026) independently increased the risk of mucositis. In head and neck tumors, 2018 year (p = 0.017), chemotherapy duration (p = 0.018), BMI > 30 (p = 0.008), radiotherapy (p = 0.037) and use of carboplatin (p = 0.046) and cyclophosphamide (p = 0.010) increased this prevalence. Conclusion Cycles of chemotherapy, sex, cytotoxicity drugs, bevacizumab and head and neck radiotherapy increase the risk of OM in solid tumors.

Download Full-text

The Efficacy of Orgotein in the Treatment of Acute Toxicity Due to Radiotherapy on Head and Neck Tumors

Tumori Journal ◽

10.1177/030089160208800507 ◽

2002 ◽

Vol 88 (5) ◽

pp. 385-389 ◽

Cited By ~ 14

Author(s):

Javier Valencia ◽

Carmen Velilla ◽

Angel Urpegui ◽

Ignacio Alvarez ◽

M Angeles Llorens ◽

...

Keyword(s):

Acute Toxicity ◽

Head And Neck ◽

Overall Response Rate ◽

Response Rate ◽

Complete Response ◽

Tumor Location ◽

Head And Neck Tumors ◽

Secondary Effects ◽

Neck Tumors ◽

Head And Neck Radiotherapy

Aims and background To assess the efficacy of orgotein in the treatment of acute secondary effects of radiotherapy on head and neck tumors. Material and methods Data were collected on 41 patients who received radiotherapy for tumors of the head and neck. Radiotherapy was the exclusive treatment in 19.5% of cases, with surgery in 24.4%, chemotherapy in 48.8%, and with both in 7.3%. The toxicity requiring use of orgotein was: oropharynx mucositis (26.8%), dysphagia (34.2%), or both (39%), in grade 2 or more according to the RTOG scale. Orgotein (8 mg im) was administered every 48 hrs until radiotherapy was finished. Results The overall response rate was 92.5%; a complete response was obtained in 12 patients (30%) and partial in 25 (62.5%). The reduction in toxicity at the end of radiotherapy was one grade in 18 patients (45%), 2 grades in 16 (40%), 3 in 2 patients (5%), and 4 grades in the only patient with grade 4 acute toxicity. A statistically significant influence was shown in obtaining complete response: laryngeal tumor location (P = 0.037), duration of radiotherapy of more than 53 days (P = 0.002), discontinuation for non-toxic reasons (P = 0.008). Conclusions We consider that orgotein is highly effective in dealing with acute secondary effects of radiotherapy on the head and neck area.

Download Full-text

Comparison of the use of Solidago chilensis (Arnica) and low-level laser therapy for the prevention of oral mucositis in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy

Research Society and Development ◽

10.33448/rsd-v10i14.22128 ◽

2021 ◽

Vol 10 (14) ◽

pp. e369101422128

Author(s):

Ana Cristina Lopes ◽

Giovana Ferreira Gonçalves ◽

Anna Cecília Dias Maciel Carneiro ◽

André Luiz Pantoja dos Santos ◽

Frederico Nobrega Tomas ◽

...

Keyword(s):

Head And Neck ◽

Laser Therapy ◽

Aqueous Extract ◽

Oral Mucositis ◽

Low Level Laser Therapy ◽

High Toxicity ◽

Low Level Laser ◽

Level Laser ◽

Head And Neck Radiotherapy ◽

Solidago Chilensis

The oral mucositis is an adverse event of radiotherapy and/or high toxicity chemotherapy. The Solidago chilensis (Arnica) has been used for its antiseptic, analgesic, healing and anti-inflammatory properties. Objective: The purpose of this study was to evaluate the uses of Arnica for oral mucositis prevention in patients submitted to radiotherapy for head and neck tumors treatment and/or high toxicity chemotherapy. Methodology: The determination of the cytotoxicity index of the aqueous extract was determined in vitro. The oral mucosa was evaluated in days 0, 10 and 14 of patients in the groups: treated with lasertherapy (L, n=18), treated with Arnica (A, n=24) and, treated with lasertherapy associated with Arnica (LA, n=4). It was considered significant p<0.05. Results: It was determined IC50=90,74 μg/mL of Arnica’s aqueous extract in SCC-4 cells. The development of oral mucositis was associated with the type of treatment for oral mucositis prevention: L, A, and LA (χ2 = 24,72, p<0.0001). The level of oral mucositis had significant interaction with the type of prevention treatment [F(2) = 9.545, p<0.0001] and, within 14 days [F(2) = 11.995, p<0.0001]. Conclusions: The results obtained suggest which the use of Solidago chilensis (Arnica) can be an important therapeutic option for treatment with low-level laser therapy for oral mucositis prevention in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy.

Download Full-text